Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
出版年份 2015 全文链接
标题
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
作者
关键词
Anti-CTLA4 antibodies, Colitis, Dermatitis, Hypohysitis, Immune related adverse events, Ipilimumab, Metastatic tumors, Oncology, Tremelimumab
出版物
BMC Medicine
Volume 13, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-09-04
DOI
10.1186/s12916-015-0455-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
- (2017) R. A. Ibrahim et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash
- (2017) Neelima N. Nallapaneni et al. Journal of the National Comprehensive Cancer Network
- New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment
- (2016) Kevin P. Murphy et al. Oncology Research and Treatment
- Ipilimumab-Induced Hepatitis on 18F-FDG PET/CT in a Patient With Malignant Melanoma
- (2015) Roy A. Raad et al. CLINICAL NUCLEAR MEDICINE
- Antitumor Granuloma Formation by CD4+ T Cells in a Patient With Rapidly Progressive Melanoma Experiencing Spiking Fevers, Neuropathy, and Other Immune-Related Toxicity After Treatment With Ipilimumab
- (2015) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- A Case Report of Orbital Inflammatory Syndrome Secondary to Ipilimumab
- (2015) Amanda D. Henderson et al. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
- Drug-Associated Dermatomyositis Following Ipilimumab Therapy
- (2015) Shirwa Sheik Ali et al. JAMA Dermatology
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
- (2014) C. Lebbe et al. ANNALS OF ONCOLOGY
- Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
- (2014) V Chiarion-Sileni et al. BRITISH JOURNAL OF CANCER
- First report of ipilimumab-induced Grover disease
- (2014) J. Munoz et al. BRITISH JOURNAL OF DERMATOLOGY
- Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
- (2014) Gary Hunter et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
- (2014) Magnus Pedersen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents
- (2014) A. Picchianti Diamanti et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosis
- (2014) Yosef Chodakiewitz et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Kidney injuries related to ipilimumab
- (2014) Hassane Izzedine et al. INVESTIGATIONAL NEW DRUGS
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma
- (2014) Evan J. Lipson et al. JOURNAL OF CLINICAL ONCOLOGY
- Humanized Mice as a Model for Aberrant Responses in Human T Cell Immunotherapy
- (2014) Nalini K. Vudattu et al. JOURNAL OF IMMUNOLOGY
- Ipilimumab-induced Autoimmune Pancytopenia in a Case of Metastatic Melanoma
- (2014) Pauline du Rusquec et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma
- (2014) Rachel L. Kyllo et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ipilimumab in patients with cancer and the management of dermatologic adverse events
- (2014) Mario E. Lacouture et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Entering the mainstream of cancer treatment
- (2014) Steven A. Rosenberg Nature Reviews Clinical Oncology
- Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
- (2014) B. Liao et al. NEURO-ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab-Induced Orbital Inflammation Resembling Graves Disease With Subsequent Development of Systemic Hyperthyroidism From CTLA-4 Receptor Suppression
- (2014) Gary E. Borodic et al. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
- Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
- (2014) H. S. Kuehn et al. SCIENCE
- Ipilimumab in patients with melanoma and autoimmune disease
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- Ipilimumab-Associated Colitis: CT Findings
- (2013) Kyung Won Kim et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Myosite orbitaire associée à un traitement par ipilimumab
- (2013) M. Lecouflet et al. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
- (2013) J. Delyon et al. ANNALS OF ONCOLOGY
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study
- (2013) P. Queirolo et al. CANCER INVESTIGATION
- Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
- (2013) Igor Z. Barjaktarevic et al. CHEST
- Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
- (2013) C. Robert et al. CLINICAL CANCER RESEARCH
- Detection of Early Onset of Hypophysitis by 18F-FDG PET-CT in a Patient With Advanced Stage Melanoma Treated With Ipilimumab
- (2013) Bernies van der Hiel et al. CLINICAL NUCLEAR MEDICINE
- Ipilimumab-Induced Immunomediated Adverse Events
- (2013) Laura Gilardi et al. CLINICAL NUCLEAR MEDICINE
- Melanoma-Associated Retinopathy Treated with Ipilimumab Therapy
- (2013) A. Audemard et al. DERMATOLOGY
- Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy
- (2013) C. Tissot et al. EUROPEAN RESPIRATORY JOURNAL
- Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy
- (2013) A. Lammert et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Ipilimumab-induced Perforating Colitis
- (2013) Kisha A. Mitchell et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphocytic Vasculitis of the Uterus in a Patient With Melanoma Receiving Ipilimumab
- (2013) David R. Minor et al. JOURNAL OF CLINICAL ONCOLOGY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
- (2013) Sofie Wilgenhof et al. JOURNAL OF IMMUNOTHERAPY
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
- (2013) Dung T. Le et al. JOURNAL OF IMMUNOTHERAPY
- The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
- (2013) Kira Minkis et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab
- (2013) Ross B. Reule et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Association Between Ipilimumab and Celiac Disease
- (2013) Nicole M. Gentile et al. MAYO CLINIC PROCEEDINGS
- Ipilimumab-induced acute severe colitis treated by infliximab
- (2013) Cecile Pagès et al. MELANOMA RESEARCH
- Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy
- (2013) Sofya Pintova et al. MELANOMA RESEARCH
- Multifocal radiculoneuropathy during ipilimumab treatment of melanoma
- (2013) Georgios Manousakis et al. MUSCLE & NERVE
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Drug-Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA-4
- (2013) Barbara L. Goldstein et al. Arthritis & Rheumatology
- Severe colitis while responding to ipilimumab in metastatic melanoma
- (2012) Marije Slingerland et al. ACTA ONCOLOGICA
- Ipilimumab-Induced Colitis on FDG PET/CT
- (2012) Ashima Lyall et al. CLINICAL NUCLEAR MEDICINE
- Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
- (2012) David E. Kleiner et al. DIGESTIVE DISEASES AND SCIENCES
- MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review
- (2012) A. Juszczak et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Enterocolitis in a Patient Being Treated With Ipilimumab for Metastatic Melanoma
- (2012) Christine Koch et al. GASTROENTEROLOGY
- Severe meningo-radiculo-nevritis associated with ipilimumab
- (2012) Flavie Bompaire et al. INVESTIGATIONAL NEW DRUGS
- Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
- (2012) Grégoire Berthod et al. JOURNAL OF CLINICAL ONCOLOGY
- A Severe Case of Ipilimumab-Induced Guillain-Barré Syndrome Revealed by an Occlusive Enteric Neuropathy
- (2012) Caroline Gaudy-Marqueste et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
- (2012) Sebastian G. Bernardo et al. MELANOMA RESEARCH
- Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient
- (2011) S. Wilgenhof et al. ANNALS OF ONCOLOGY
- Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
- (2011) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Association of Ipilimumab Therapy for Advanced Melanoma with Secondary Adrenal Insufficiency: A Case Series
- (2011) Le Min et al. Endocrine Practice
- Lymphocytic Colitis Secondary to Ipilimumab Treatment
- (2011) Alejandro García-Varona et al. INFLAMMATORY BOWEL DISEASES
- Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
- (2011) Katarzyna D. Chmiel et al. JOURNAL OF CLINICAL ONCOLOGY
- Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma
- (2011) Michela Maur et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission
- (2011) Wouter V. Vogel et al. JOURNAL OF CLINICAL ONCOLOGY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Hyponatremia associated with Ipilimumab-induced hypophysitis
- (2011) Zachary R. Barnard et al. MEDICAL ONCOLOGY
- Hemophilia A Induced by Ipilimumab
- (2011) Julie Delyon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma
- (2011) S Ahmad et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
- (2010) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
- (2010) C. Ralph et al. CLINICAL CANCER RESEARCH
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
- Autoimmunity and treatment outcome in melanoma
- (2010) Marna G Bouwhuis et al. CURRENT OPINION IN ONCOLOGY
- Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
- (2010) Le Min et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- (2010) Ki Y. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
- (2010) Kaan Harmankaya et al. MEDICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Has the Microbiota Played a Critical Role in the Evolution of the Adaptive Immune System?
- (2010) Y. K. Lee et al. SCIENCE
- Clinical Studies With Anti–CTLA-4 Antibodies in Non-melanoma Indications
- (2010) Luana Calabrò et al. SEMINARS IN ONCOLOGY
- Ipilimumab-Induced Hypophysitis: MR Imaging Findings
- (2009) K.J. Carpenter et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
- (2009) David R. Minor et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
- (2009) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
- (2009) James D. Lord et al. DIGESTIVE DISEASES AND SCIENCES
- Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells
- (2009) Hélène Bour-Jordan et al. IMMUNOLOGICAL REVIEWS
- Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade
- (2009) Willemijn B. Breunis et al. JOURNAL OF IMMUNOTHERAPY
- Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
- (2009) Mojtaba Akhtari et al. JOURNAL OF IMMUNOTHERAPY
- Inflammatory Enteric Neuropathy With Severe Constipation After Ipilimumab Treatment for Melanoma
- (2009) Shailender Bhatia et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient
- (2009) Katharina C. Kaehler et al. MELANOMA RESEARCH
- Anti-CTLA4 Antibody–Induced Lupus Nephritis
- (2009) Fouad Fadel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
- (2008) Ilyssa O. Gordon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
- (2008) A. Eckert et al. DERMATOLOGY
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search